Ambroxol as a Treatment for Parkinson's Disease Dementia

Clinical Trial ID NCT02914366

PubWeight™ 0.00^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02914366

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains.	Ann Neurol	2012	2.20
2	Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough.	Lancet Neurol	2004	2.11
3	Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease.	Blood Cells Mol Dis	2012	1.58
4	Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies.	Proc Natl Acad Sci U S A	2013	1.45
5	Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease.	J Biol Chem	2009	1.39
6	Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease.	Mov Disord	2007	1.13
7	Ambroxol in the 21st century: pharmacological and clinical update.	Expert Opin Drug Metab Toxicol	2008	0.92
8	The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice.	Brain Dev	2012	0.91
9	An alternative to steroids for prevention of respiratory distress syndrome (RDS): multicenter controlled study to compare ambroxol and betamethasone.	J Perinat Med	1987	0.82
10	Antenatal use of ambroxol for the prevention of infant respiratory distress syndrome.	J Obstet Gynaecol Res	2000	0.81
11	Changes in pulmonary function in preterm infants recovering from RDS following early treatment with ambroxol: results of a randomized trial.	Pediatr Pulmonol	1999	0.81
12	Ambroxol for prevention and treatment of hyaline membrane disease.	Eur Respir J Suppl	1989	0.77